High-dose rapid and standard induction chemotherapy for patients aged over 1 year with stage 4 neuroblastoma: a randomised trial

Pearson, Andrew D.J.; Pinkerton, CR; Lewis, Ian; Imeson, John; Ellershaw, Caroline; Machin, David

doi:10.1016/s1470-2045(08)70069-x

Cited by 319 publications

(247 citation statements)

References 20 publications

Supporting

Mentioning

226

Contrasting

Unclassified

Order By: Relevance

“…Despite a variety of changes in the treatment strategy for patients with high-risk neuroblastoma over the years, this group continues to have poor outcomes and remains one of the most challenging to treat. Long-term survival rates for children with high-risk neuroblastoma are currently around 40-50% in large cooperative group studies [61][62][63][64]. Although the treatment regimens used for children with high-risk neuroblastoma have evolved somewhat over the past decade, the standard regimens continue to have 4 main components: (1) Induction chemotherapy, (2) Local Control, (3) Consolidation, and (4) Maintenance therapy.…”

Section: Treatment -High-risk Neuroblastomamentioning

confidence: 99%

“…Rapid COJEC was administered in 8 cycles, separated by 10 day intervals, allowing for completion of induction within 70 days from administration of the first drug. A randomized trial showed no difference in outcomes between patients treated with the rapid COJEC regimen compared to those treated with standard OPEC/OJEC induction therapies [62], and due to the ability to deliver induction over a shorter timeframe, rapid COJEC has been incorporated into the standard treatment regimen for these children with highrisk neuroblastoma.…”

Section: Inductionmentioning

confidence: 99%

See 1 more Smart Citation

Overview and recent advances in the treatment of neuroblastoma

Whittle

Smith

Doherty

et al. 2017

Expert Review of Anticancer Therapy

311

258

View full text Add to dashboard Cite

Introduction: Children with neuroblastoma have widely divergent outcomes, ranging from cure in >90% of patients with low risk disease to <50% for those with high risk disease. Recent research has shed light on the biology of neuroblastoma, allowing for more accurate risk stratification and treatment reduction in many cases, although newer treatment strategies for children with high-risk and relapsed neuroblastoma are needed to improve outcomes. Areas covered: Neuroblastoma epidemiology, diagnosis, risk stratification, and recent advances in treatment of both newly diagnosed and relapsed neuroblastoma. Expert commentary: The identification of newer tumor targets and of novel cell-mediated immunotherapy agents may lead to novel therapeutic approaches, and clinical trials for regimens designed to target individual genetic aberrations in tumors are underway. A combination of therapeutic modalities will likely be required to improve survival and cure rates for patients with high-risk neuroblastoma.ARTICLE HISTORY

show abstract

Section: Treatment -High-risk Neuroblastomamentioning

confidence: 99%

Section: Inductionmentioning

confidence: 99%

Overview and recent advances in the treatment of neuroblastoma

Whittle

Smith

Doherty

et al. 2017

Expert Review of Anticancer Therapy

311

258

View full text Add to dashboard Cite

show abstract

“…All patients received HR-NB induction regimens. 5,6,30,31 Therapy before relapse included isotretinoin in 85 (84%) patients and anti-G D2 mAb in 51 (50%) patients. Sites of relapse were osteomedullary (BM and/or bone) (nD34), osteomedullary plus soft tissue (n D 31), or soft tissue (n D 36).…”

Section: Clinical Characteristicsmentioning

confidence: 99%

“…1 Before the routine use of immunotherapy, 3-5 year progression-free survival (PFS) rates in national studies were 20-40%, [2][3][4][5][6] even with inclusion of patients with what is now known to be intermediate-risk NB. 7 The randomized study of the Children's Oncology Group showed significantly better outcome in patients treated post-ASCT with the anti-G D2 chimeric mAb ch14.18 plus granulocyte-macrophage colony-stimulating factor (GM-CSF) plus interleukin-2.…”

Section: Introductionmentioning

confidence: 99%

Prolonged progression-free survival after consolidating second or later remissions of neuroblastoma with Anti-G_D2immunotherapy and isotretinoin: a prospective Phase II study

et al. 2015

View full text Add to dashboard Cite

Relapse of high-risk neuroblastoma (HR-NB) is deemed invariably fatal yet increasing numbers of HR-NB patients achieve a second complete/very good partial remission (CR/VGPR), hence the urgency to find a successful consolidative therapy. Identifying efficacy in patients without assessable disease, however, is problematic. We report the first study providing outcome data for this group of patients with poor prognosis. To prevent another relapse, HR-NB patients in second or later CR/VGPR received the anti-G D2 murine antibody 3F8 plus granulocyte-macrophage colony-stimulating factor plus isotretinoin in a Phase II trial. Upon meeting the target aim for progression-free survival (PFS) in the initial cohort of 33 patients, the trial was amended to allow patients who developed human anti-mouse antibody (HAMA) to receive rituximab to ablate HAMA with or without low-dose maintenance chemotherapy until immunotherapy could resume. For the total of 101 study patients, 5-year PFS and overall survival (OS) rates were 33% § 5% and 48% § 5%, respectively. Among the 33 long-term progression-free survivors, 19 had MYCN amplification, 19 had previously received anti-G D2 immunotherapy plus isotretinoin (as first-line therapy), and 15 never received maintenance chemotherapy. In a multivariate analysis of prognostic factors, only absence of minimal residual disease in bone marrow after 2 cycles of immunotherapy and before initiation of isotretinoin or anti-HAMA therapy was significantly favorable for both PFS and OS. Therefore, long-term PFS is possible for HR-NB patients who achieve at least a second CR/VGPR and receive consolidation that includes anti-G D2 immunotherapy plus isotretinoin, even if the patients received these biological treatments before relapse. Results from this prospective study will aid in the development of future Phase II studies for this growing ultra high-risk patient population.

show abstract

“…It has extensive pathologic and molecular heterogeneity which decides the significant clinical diversity from spontaneous regression to highlyaggressive and drug resistant metastatic disease. Although multimodal chemotherapy/radiotherapies/immunotherapy significantly improves patient survival during the last few decades, some patients will continue to relapse and die of this malignancy because of de novo or acquired drug resistance, especially for high-risk neuroblastoma patients [1,2].…”

Section: Introductionmentioning

confidence: 99%

Advances in ALK Targeted Therapy for Neuroblastoma

Zhang¹,

Baruchel²

2017

J Oncol Transl Res

View full text Add to dashboard Cite

High-dose rapid and standard induction chemotherapy for patients aged over 1 year with stage 4 neuroblastoma: a randomised trial

Cited by 319 publications

References 20 publications

Overview and recent advances in the treatment of neuroblastoma

Overview and recent advances in the treatment of neuroblastoma

Prolonged progression-free survival after consolidating second or later remissions of neuroblastoma with Anti-G_D2immunotherapy and isotretinoin: a prospective Phase II study

Advances in ALK Targeted Therapy for Neuroblastoma

Contact Info

Product

Resources

About

High-dose rapid and standard induction chemotherapy for patients aged over 1 year with stage 4 neuroblastoma: a randomised trial

Cited by 319 publications

References 20 publications

Overview and recent advances in the treatment of neuroblastoma

Overview and recent advances in the treatment of neuroblastoma

Prolonged progression-free survival after consolidating second or later remissions of neuroblastoma with Anti-GD2immunotherapy and isotretinoin: a prospective Phase II study

Advances in ALK Targeted Therapy for Neuroblastoma

Contact Info

Product

Resources

About

Prolonged progression-free survival after consolidating second or later remissions of neuroblastoma with Anti-G_D2immunotherapy and isotretinoin: a prospective Phase II study